Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Copperdigger’s post must have explained it.
So this post on 10/2 was baloney?
“I have no clue how ZENA shares showed up in my Charles Schwab account… was there a reverse merger? What was the ticker symbol before the ticker symbol
Changed to ZENA?? TIA. Thanks in advance”
Did people here get Zena shares for having owned Epaz? I own 1 mil+ shares of Epaz, but don’t see any Zena shares in my Fidelity accounts
Zena may not be listed in Epaz' Filings, but their paid promoter sure makes it appear that way. If their promoter is responsible for the misleading claim, then Epaz should have issued a clarification statement.
"Epazz, Inc. (OTC: EPAZ), a mission-critical provider of drone technology, blockchain mobile apps and cloud-based business software solutions, just announced that one of its holdings, ZenaDrone, Inc., was selected and funded for the US Air Force Small Business Innovation Research (SBIR) Award for phase I of the innovative defense-related dual-purpose technology.
The company is working with an assigned US Air Force contract agent to complete the paperwork and begin the contract over the next year. ZenaDrone has 90 days to complete the contract to apply for SBIR phase II, which will include funding up to $1.2 million if successful.
Looks like I did. I don’t know how they can issue press releases, even to a paid service, that refer to Zena as a “subsidiary”.
My mistake then, no thanks to Jedi.
It might have been my ignorance, but I bought EPAZ thinking that Zena was a subsidiary, and thereby potentially contributing to the value of Epaz. Therefore if spun off, the Epaz shareholders have a right to a portion of the new shares.
And how many shares do we get??
A study shows that rising levels of brain protein Aß42, not the reduction of amyloid plaques, better explains the cognitive benefits of new Alzheimer’s drugs. This finding challenges the traditional focus on plaques in Alzheimer’s treatment.
A new study reveals that the rise in protein levels due to new Alzheimer’s drugs may explain the slowing of cognitive decline just as effectively as the reduction of amyloid plaques.
In a study that questions the effectiveness of newly approved monoclonal antibodies in reducing cognitive decline in Alzheimer’s patients by clearing amyloid, researchers from the University of Cincinnati discovered that an unintended rise in a critical brain protein’s levels correlates just as strongly with cognitive benefits.
Led by UC’s Alberto Espay, MD, the research was published in the journal Brain.
Study background
For decades, the prevailing theory in the field has stated that a protein made up of 42 amino acids called amyloid-beta 42 (Aß42) hardens into clumps called amyloid plaques, and those plaques damage the brain, causing Alzheimer’s disease.
Espay and team have hypothesized that normal, soluble Aß42 in the brain is crucial for neuron health and that the loss of Aß42, rather than the buildup of plaques, drives Alzheimer’s. This includes published research that suggests dementia occurs not when plaque levels are high but when Aß42 levels drop very low.
According to Espay’s research, the transformation of Aß42 into plaques appears to be the brain’s normal response to biological, metabolic, or infectious stress.
Alberto Espay
Alberto Espay, MD, MSc, professor of neurology at the UC College of Medicine and Director and Endowed Chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders. Credit: Colleen Kelley/UC Brand + Creative
“Most of us will accrue amyloid plaques in our brains as we age, and yet very few of us with plaques go on to develop dementia,” said Espay, professor of neurology in the UC College of Medicine and director and endowed chair of the James J. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders at the UC Gardner Neuroscience Institute. “Yet the plaques remain the center of our attention in biomarker development and therapeutic strategies.”
Study details
Recently, several new monoclonal antibody medications designed to remove amyloid from the brain were approved after showing they lessened cognitive decline in clinical trials.
Espay and his colleagues noticed that these drugs unintentionally increased levels of AĂź42.
“Amyloid plaques don’t cause Alzheimer’s, but if the brain makes too much of it while defending against infections, toxins, or biological changes, it can’t produce enough Aß42, causing its levels to drop below a critical threshold,” Espay explained. “That’s when dementia symptoms emerge.”
The team analyzed data from nearly 26,000 patients enrolled in 24 randomized clinical trials of these new antibody treatments, assessing cognitive impairment and differences in levels of AĂź42 before and after treatment. They found that higher levels of AĂź42 after treatment were independently associated with slower cognitive impairment and clinical decline.
“All stories have two sides — even the one we have told ourselves about how anti-amyloid treatments work: by lowering amyloid,” Espay said. “In fact, they also raise the levels of Aß42. Even if this is unintended, it is why there may be a benefit. Our study shows that we can predict changes in cognitive outcomes in anti-amyloid trials at least as well by the increases in Aß42 as by the decreases in amyloid.”
Espay said these findings fit well into his larger hypothesis about the root cause of Alzheimer’s, as increasing levels of Aß42 appear to improve cognition.
“If the problem with Alzheimer’s is the loss of the normal protein, then increasing it should be beneficial, and this study showed that it is,” he said. “The story makes sense: Increasing Aß42 levels to within the normal range is desirable.”
However, Espay believes these results also present a conundrum for clinicians because removing amyloid from the brain is toxic and may cause the brain to shrink faster after antibody treatment.
“Do we give patients an anti-protein treatment to increase their protein levels? I think the end, increasing Aß42, doesn’t justify the means, decreasing amyloid,” Espay said. Therapies that directly increase Aß42 levels without targeting amyloid are a focus of research for Espay and his group
We’re rich!
Why post this garbage twice?
Hmmm. Interesting.
Clawing its way up slowly. Breakout at .10. Wonder who’s buying?
Could the absence of information for current shareholders be due to a “quiet period” regarding the spinoff?
I’m referring to the supposed IPO for Zena.
Lack of news is very concerning. Somebody needs to call.
We’d better get shares. I bought Epaz because of the drone business. If we don’t, I smell law suit.
I agree, but shouldn’t that have been on that F-1 that recently came out? Too long for me to wade through🥴.
I saw a story on a Portland, OR tv station this am about a Salem (Oregon) area school planning to try out a detection system made by Evolve, an east coast company that seems to be doing very well and likely eating DTII's lunch. The boys down in Del Mar better get off the beach and get their butts in gear. I was down in Del Mar 2 weeks ago. Should have done a drive by to see if anyone was at work. Unlikely, as it was a beautiful day down there.
Correction:102 mil shares.
Anyone calculate the offering price if the 192 mil shares sell? Looks like 6.8 cents each, with a lockout period of 180 days. Anyone correct me if I hav calculated incorrectly.
With you on all that!
Their administrative offices seem to be top heavy. Why have a Chicago office when PHX is just as easy to communicate with? I think once a military contract comes in there will be more civilian interest. Companies don't want to invest in a product that may suddenly lose support. Neither does the military, but the military has their budget backing it up.
Yes, cash on hand could be scary..
How did you cone up with the 03/21 date?
I have always assumed that the selling of shares was in order to pay salaries and keep the lights on.
Tie in with Amazon seems most logical. This drone has the lifting capacity and the range to meet their urgent and high priority delivery needs.
Yes. Under water till it hits a penny. About 609k shares.
Well spoken Kevin.
I’m holding my nose with my investment here. Hoping for a bit of a profit before wiping this dog shit off my shoes.
How about revealing your source?? Drones are already in widespread use, so highly unlikely to happen.
It seems it would be important for anyone passing through a security system that radiates on a daily basis. I would not like a child of mine passing through even low level radiation every day at school, when 20 or 30 years later they might be diagnosed with a blood cancer like leukemia. Or even for adults like those who work in a courthouse who have to enter on a daily basis. I do also wonder if this system will detect an all plastic ghost gun?
I have not researched it, but does anyone know if there are other non-radiating systems on the market?
Tax loss selling kicking in.
Thanks. I got burned on SNPX, so gonna wait this one out.
How long is this study?
So the drone can lift 80 lbs and stay up an hour; have they ever said the max altitude it can fly at?
Thanks for the info.
I emailed the company 2 days ago; got no response. Anyone on this board live in Austin who could go knock on their door? I'll try phoning tomorrow.
Mystery is what news is about to drop…
When clicking on "newer" or "older", you should not have to scroll up or down to find the next new or old. The beta will greatly slow the scrolling process.. The old version did not always allow this, but this is far worse.